| Literature DB >> 33538817 |
Tomohiro Takano1, Takayuki Matsumura1, Yu Adachi1, Kazutaka Terahara1, Saya Moriyama1, Taishi Onodera1, Ayae Nishiyama1, Ai Kawana-Tachikawa2, Shoji Miki2, Kaori Hosoya-Nakayama2, Midori Nakamura-Hoshi2, Sayuri Seki2, Natsuo Tachikawa3, Yukihiro Yoshimura3, Nobuyuki Miyata3, Hiroshi Horiuchi3, Hiroaki Sasaki3, Kazuhito Miyazaki3, Noriko Kinoshita4, Tsutomu Sudo4, Yutaro Akiyama4, Rubuna Sato4, Tadaki Suzuki5, Tetsuro Matano2, Yoshimasa Takahashi1.
Abstract
An expanded myeloid cell compartment is a hallmark of severe coronavirus disease 2019 (COVID-19). However, data regarding myeloid cell expansion have been collected in Europe, where the mortality rate by COVID-19 is greater than those in other regions including Japan. Thus, characteristics of COVID-19-induced myeloid cell subsets remain largely unknown in the regions with low mortality rates. Here, we analyzed cellular dynamics of myeloid-derived suppressor cell (MDSC) subsets and examined whether any of them correlate with disease severity and prognosis, using blood samples from Japanese COVID-19 patients. We observed that polymorphonuclear (PMN)-MDSCs, but not other MDSC subsets, transiently expanded in severe cases but not in mild or moderate cases. Contrary to previous studies in Europe, this subset selectively expanded in survivors of severe cases and subsided before discharge, but such transient expansion was not observed in non-survivors in Japanese cohort. Analysis of plasma cytokine/chemokine levels revealed positive correlation of PMN-MDSC frequencies with IL-8 levels, indicating the involvement of IL-8 on recruitment of PMN-MDSCs to peripheral blood following the onset of severe COVID-19. Our data indicate that transient expansion of the PMN-MDSC subset results in improved clinical outcome. Thus, this myeloid cell subset may be a predictor of prognosis in cases of severe COVID-19 in Japan. © The Japanese Society for Immunology. 2021. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.Entities:
Keywords: SARS-CoV-2; chemokine; cytokine; innate immunity; myeloid-derived suppressor cell
Mesh:
Substances:
Year: 2021 PMID: 33538817 PMCID: PMC7928855 DOI: 10.1093/intimm/dxab005
Source DB: PubMed Journal: Int Immunol ISSN: 0953-8178 Impact factor: 4.823